Sorry, not familiar with VSTM but did a little reading about the drug. This is very very early, only a phase 1/1B trial so they have a ways to go yet. For those interested, here is a copy and past of what V-6063 is. I also do not know about FAK inhibitors either, but I will read up. Thanks for bringing this to the board, always interesting to read about emerging technologies.
VS-6063 is an oral small molecule inhibitor of focal adhesion kinase (FAK) which is a critical pathway for cancer stem cells. VS-6063 was well-tolerated and demonstrated signs of clinical activity in a Phase 1 study in advanced solid tumors. VS-6063 is currently in a Phase 1/1b study in patients with advanced ovarian cancer, where VS-6063 is being tested in combination with paclitaxel. VS-6063 is anticipated to enter a potentially pivotal study in mesothelioma midyear 2013.
Chinese Hamsters